US 8030317
MAPK/ERK kinase inhibitors
granted A61PA61P1/00A61P11/00
Quick answer
US patent 8030317 (MAPK/ERK kinase inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Oct 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P1/00, A61P11/00, A61P11/06, A61P11/08